WO2012008788A3 - 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물 및 이의 용도 {composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient and the use thereof} - Google Patents

세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물 및 이의 용도 {composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient and the use thereof} Download PDF

Info

Publication number
WO2012008788A3
WO2012008788A3 PCT/KR2011/005212 KR2011005212W WO2012008788A3 WO 2012008788 A3 WO2012008788 A3 WO 2012008788A3 KR 2011005212 W KR2011005212 W KR 2011005212W WO 2012008788 A3 WO2012008788 A3 WO 2012008788A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
liver diseases
fatty liver
active ingredient
Prior art date
Application number
PCT/KR2011/005212
Other languages
English (en)
French (fr)
Other versions
WO2012008788A2 (ko
Inventor
이병훈
윤호권
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Priority to US13/809,157 priority Critical patent/US9539226B2/en
Publication of WO2012008788A2 publication Critical patent/WO2012008788A2/ko
Publication of WO2012008788A3 publication Critical patent/WO2012008788A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물에 관한 것으로, 본 발명에 따른 알코올에 의해 활성화된 지방산 생합성 조절전사인자(SREBP-1)를 전사 억제함으로서 간 조직 내의 중성지방 축적을 억제하여 지방간 질환의 예방 및 치료용 조성물 및 건강기능식품으로 유용하게 이용될 수 있다.
PCT/KR2011/005212 2010-07-16 2011-07-15 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물 및 이의 용도 {composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient and the use thereof} WO2012008788A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/809,157 US9539226B2 (en) 2010-07-16 2011-07-15 Composition containing serine as an active ingredient for the prevention and treatment of fatty liver diseases, and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0068784 2010-07-16
KR1020100068784A KR101213825B1 (ko) 2010-07-16 2010-07-16 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2012008788A2 WO2012008788A2 (ko) 2012-01-19
WO2012008788A3 true WO2012008788A3 (ko) 2012-05-18

Family

ID=45469950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/005212 WO2012008788A2 (ko) 2010-07-16 2011-07-15 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물 및 이의 용도 {composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient and the use thereof}

Country Status (3)

Country Link
US (1) US9539226B2 (ko)
KR (1) KR101213825B1 (ko)
WO (1) WO2012008788A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
CN112469403A (zh) * 2018-06-07 2021-03-09 国立大学法人金泽大学 肾损伤的预防或治疗用的药物组合物
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
KR20200084164A (ko) * 2019-01-02 2020-07-10 엘지이노텍 주식회사 사육장 환경 관리 장치
US20240173253A1 (en) * 2021-03-19 2024-05-30 Astrogen, Inc. Liquid preparation of l-serine or pharmaceutically acceptable salt thereof and method for preparing same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980702436A (ko) * 1995-02-23 1998-07-15 하인쯔 쉬나이더, 미첼 오르진거 아미노산 조성물 및 임상용 영양물내에 이의 사용 방법
KR20040094749A (ko) * 2002-03-01 2004-11-10 닛신 파마 가부시키가이샤 간 질환, 고지혈증 및 당뇨병 치료제
KR100969170B1 (ko) * 2010-01-19 2010-07-14 연세대학교 산학협력단 여지핵 추출물을 포함하는 지방간 또는 비만의 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JP2001114681A (ja) * 1999-10-18 2001-04-24 Ajinomoto Co Inc ケトーシス改善剤
US20040192751A1 (en) * 2001-03-15 2004-09-30 Takeshi Abe Amino acid composition for ameliorating liver failure
JP2010018522A (ja) 2007-03-23 2010-01-28 Hiroshima Univ アディポネクチン産生促進剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980702436A (ko) * 1995-02-23 1998-07-15 하인쯔 쉬나이더, 미첼 오르진거 아미노산 조성물 및 임상용 영양물내에 이의 사용 방법
KR20040094749A (ko) * 2002-03-01 2004-11-10 닛신 파마 가부시키가이샤 간 질환, 고지혈증 및 당뇨병 치료제
KR100969170B1 (ko) * 2010-01-19 2010-07-14 연세대학교 산학협력단 여지핵 추출물을 포함하는 지방간 또는 비만의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US20130116321A1 (en) 2013-05-09
US9539226B2 (en) 2017-01-10
KR101213825B1 (ko) 2012-12-18
KR20120008125A (ko) 2012-01-30
WO2012008788A2 (ko) 2012-01-19

Similar Documents

Publication Publication Date Title
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
WO2012008788A3 (ko) 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물 및 이의 용도 {composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient and the use thereof}
WO2012085523A3 (en) Skin sanitizer compositions comprising alcohol based emulsion
WO2012108689A3 (ko) 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
MY171340A (en) Sweetness and/or milk flavor enhancer
WO2009007412A3 (fr) Deglycation des ages
WO2009117316A3 (en) Pharmaceutical compositions having desirable bioavailability
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
WO2011126250A3 (ko) Pde5 억제제를 함유하는 피부 주름 개선용 조성물
WO2012108677A3 (ko) 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
WO2011159129A3 (ko) 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
WO2010039654A3 (en) Topical treatment of skin infection
WO2011080254A3 (en) Fungicide hydroximoyl-heterocycles derivatives
MX353580B (es) Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel.
WO2013068960A3 (en) Monounsaturated fatty acid for nailcare
WO2011118957A3 (ko) 파프리카 추출물을 함유하는 염증, 알레르기 또는 천식 질환 치료용 조성물
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
WO2013000895A9 (en) Dha and epa in the reduction of oxidative stress
WO2012081831A3 (en) Composition comprising the extract of loranthus yadoriki sieb having monoamine oxidase-inhibiting activity
WO2013068962A3 (en) Monounsaturated fatty acid for nailcare
WO2008153784A3 (en) Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors
WO2012102560A3 (ko) 신규한 4-ｏ-메틸호노키올 유도체 및 이를 유효성분으로 포함하는 염증질환 치료용 조성물
WO2011041634A8 (en) Pyrazole inhibitors of phosphatidylinositol 3-kinase
WO2014060276A3 (en) Cosmetic use of a monounsaturated fatty acid or one of its salts and/or of its esters or amides as deodorant active agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11807073

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13809157

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11807073

Country of ref document: EP

Kind code of ref document: A2